Active Pharmaceutical Ingredients / Global Supply

Four decades of
API chemistry.

Established process chemistry, regulated-market manufacturing and global customer relationships form the scientific and manufacturing foundation of Morepen.

Explore APIs Manufacturing & quality

Building today. Transforming tomorrow.

MOREPEN / API / GLOBAL MANUFACTURINGChemistry built for reliable global supply.

0+Years of pharmaceutical experience

0+Countries served

0 KLAPI / CDMO reactor capacity

0Consecutive NIL Form 483 inspections reported

Current installed API/CDMO reactor capacity: 614 KL. Inspection milestone: company disclosure dated 17 April 2026. Site-specific qualification applies.

Global pharmaceutical manufacturing

Chemistry, compliance
and scale — connected.

Morepen combines more than four decades of API manufacturing experience with an expanding CDMO platform, drug-product development capabilities and healthcare businesses. The focus is increasingly on long-duration global partnerships, regulated-market execution and science-led growth.

Discover Morepen Explore CDMO

01SCIENCE

Deep chemistry foundation

Established small-molecule API expertise, process development and scale-up form the scientific base for higher-value customer programs.

02DEVELOPMENT

Integrated capabilities

Custom development, analytical work, technology transfer and selected drug-product programs connect development with manufacturing.

03MANUFACTURING

Regulated-market execution

Manufacturing infrastructure, quality systems and export experience support customers across regulated and emerging markets.

04PARTNERSHIP

Long-duration relationships

Morepen is expanding from transaction-led supply toward recurring programs, commercial CDMO execution and deeper global partnerships.

Pharmaceutical development & manufacturing

API strength.
Connected capabilities.

Morepen combines established API manufacturing with expanding development, analytical, scale-up and commercial manufacturing capabilities for global pharmaceutical partners.

Active Pharmaceutical Ingredients

A global API platform built on process chemistry, regulated-market manufacturing and long-standing customer relationships.

Explore capability

CDMO & Custom Development

End-to-end support from key intermediates and API/drug substance development through analytical work, scale-up, technology transfer and commercial supply.

Explore capability

Drug Product Development

Formulation, analytical development, stability, regulatory batches and dossier support, demonstrated through the company's first U.S. ANDA submission.

Explore capability

Explore API portfolio Explore CDMO services

Stay informed

News & announcements

All news Investor centre

Business announcement28 SEP 2026

First U.S. ANDA submission expands integrated development

View announcement

Results announcement04 AUG 2026

Q1 FY27: commercial execution and record quarterly results

View announcement

Business announcement17 APR 2026

Masulkhana inspection completed with NIL Form 483

View announcement

Selected recent publications · complete reports and disclosures in the Investor centre.

Morepen 2.0

From product supply to
deeper global partnerships.

APIs remain Morepen's scientific and manufacturing foundation. The current growth phase builds on that base through commercial CDMO programs, integrated development capabilities and disciplined expansion of manufacturing scale.

INR 8,250 million

CDMO mandate in commercial execution

INR 580 million commercial dispatches reported in Q1 FY27

Explore CDMO Investor centre

Revenue mix

Growing contribution from longer-duration customer programs and value-added manufacturing.

Capability

Deeper process chemistry, analytical, regulatory and finished-dosage development capabilities.

Scale

Capacity expansion aligned with customer programs, utilities, quality systems and execution readiness.

Partnership

Greater emphasis on customer continuity, supply reliability and multi-year global relationships.

Manufacturing & supply

Scale backed by process
depth and execution.

614KL installed API / CDMO reactor capacity

Morepen's manufacturing network in Himachal Pradesh supports small-molecule APIs and CDMO programs for domestic and international customers. Expansion is being phased alongside customer demand, utilities, finishing areas, laboratories and environmental systems.

Baddi

High-volume manufacturing and expansion platform.

Masulkhana

Established API manufacturing and regulated-market track record.

Process scale-up

Technology transfer and manufacturing integration.

Supply continuity

Quality, reliability and customer commitments.

Explore manufacturing

Morepen manufacturing facility aerial view in Himachal Pradesh

Quality & regulatory compliance

Global trust is earned
through repeatable systems.

Quality, data integrity, regulatory readiness and continuity of supply are central to long-term pharmaceutical partnerships.

Four consecutive USFDA inspections reported with Nil Form 483 observations

MASULKHANA / 17 APRIL 2026

A site-specific quality milestone.

The April 2026 inspection at the Masulkhana API facility concluded without Form 483 observations. Morepen's wider regulatory footprint includes engagement across multiple regulated markets, with scope varying by site, product and filing.

Read the inspection disclosure

Quality & credentials

Our healthcare businesses

Different needs.
Distinct businesses.

Medical Devices, Rx and OTC each have a clear place in our healthcare story, alongside Morepen's pharmaceutical development and manufacturing platform.

Explore Healthcare Businesses